Johnson & Johnson (NYSE:JNJ) has been assigned an average recommendation of “Hold” from the eighteen brokerages that are currently covering the stock. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $124.04.
A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, January 9th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $124.53 price target on the stock. in a research note on Thursday, February 23rd. Goldman Sachs Group Inc cut their price target on shares of Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 25th. Wells Fargo & Co lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price target for the company from $112.28 to $112.80 in a research note on Thursday, January 26th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $110.00 price target (up previously from $107.00) on shares of Johnson & Johnson in a research note on Thursday, January 5th.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.09% during midday trading on Thursday, reaching $121.76. The company’s stock had a trading volume of 6,021,721 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $129.00. The company has a market capitalization of $330.38 billion, a P/E ratio of 20.53 and a beta of 0.74. The stock has a 50 day moving average of $125.17 and a 200-day moving average of $118.12.
COPYRIGHT VIOLATION WARNING: This story was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://transcriptdaily.com/2017/04/22/johnson-johnson-jnj-receives-122-40-average-price-target-from-analysts.html.
In other Johnson & Johnson news, VP Paulus Stoffels sold 22,000 shares of the company’s stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the sale, the vice president now directly owns 127,650 shares of the company’s stock, valued at $14,972,068.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.11% of the company’s stock.
A number of hedge funds have recently bought and sold shares of JNJ. Itau Unibanco Holding S.A. purchased a new stake in Johnson & Johnson during the third quarter valued at about $104,000. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $117,000. Hefty Wealth Partners increased its position in Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock valued at $132,000 after buying an additional 951 shares in the last quarter. Finally, Empirical Finance LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $144,000. 65.30% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
